NEUROCRINE BIOSCIENCES INC Form 8-K July 28, 2011

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## FORM 8-K

## **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of the earliest event reported): July 28, 2011

# NEUROCRINE BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

**Delaware** (State or other jurisdiction of

0-22705 (Commission 33-0525145 (IRS Employer

incorporation or organization)

File Number)


**Identification No.)** 

12780 El Camino Real, San Diego, California
(Address of principal executive offices)
Registrant s telephone number, including area code: (858) 617-7600

92130 (Zip Code)

N/A

(Former name or former address, if changed since last report.)



- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))

#### ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

On July 28, 2011, Neurocrine Biosciences, Inc. announced its financial results for the second quarter ended June 30, 2011. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act ) or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

#### ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(d) EXHIBITS.

**Exhibit** 

Number Description of Exhibit

99.1 Press Release dated July 28, 2011

#### **SIGNATURES**

Pursuant to the requirements of the Securities and Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: July 28, 2011 NEUROCRINE BIOSCIENCES, INC.

/s/ TIMOTHY P. COUGHLIN Timothy P. Coughlin Vice President and Chief Financial Officer

### EXHIBIT INDEX

Exhibit

Number Description of Exhibit

99.1 Press Release dated July 28, 2011